{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:37:05Z","timestamp":1790458625090,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41409-018-0102-z","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T15:19:34Z","timestamp":1516720774000},"page":"852-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)"],"prefix":"10.1038","volume":"53","author":[{"given":"Peter","family":"Bader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zyrafete","family":"Ku\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Bakhtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniko","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4328-9612","authenticated-orcid":false,"given":"Kriszti\u00e1n M.","family":"K\u00e1llay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Walter","family":"Sykora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"von Luettichau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Herter-Sprie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ashab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Jenkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alsultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Buechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Kelemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jarisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Soerensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Salzmann-Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhard","family":"Seifried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Ku\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"102_CR1","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150\u201363.","journal-title":"Biol Blood Marrow Transplant"},{"key":"102_CR2","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","volume":"109","author":"HJ Deeg","year":"2007","unstructured":"Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119.","journal-title":"Blood"},{"key":"102_CR3","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(15)00224-0","volume":"3","author":"S Hashmi","year":"2016","unstructured":"Hashmi S, Ahmed M, Murad MH, Litzow MR, Adams RH, Ball LM, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3:e45\u2013e52.","journal-title":"Lancet Haematol"},{"key":"102_CR4","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2062\u20138.","journal-title":"Leukemia"},{"key":"102_CR5","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K Blanc Le","year":"2004","unstructured":"Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439\u201341.","journal-title":"Lancet"},{"key":"102_CR6","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","volume":"81","author":"O Ringden","year":"2006","unstructured":"Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390\u20137.","journal-title":"Transplantation"},{"key":"102_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Blanc Le","year":"2008","unstructured":"Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579\u201386.","journal-title":"Lancet"},{"key":"102_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.bbmt.2010.03.017","volume":"16","author":"G Lucchini","year":"2010","unstructured":"Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant. 2010;16:1293\u2013301.","journal-title":"Biol Blood Marrow Transplant"},{"key":"102_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bcmd.2007.06.021","volume":"40","author":"I Muller","year":"2008","unstructured":"Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008;40:25\u201332.","journal-title":"Blood Cells Mol Dis"},{"key":"102_CR10","first-page":"225","volume":"3","author":"IB Resnick","year":"2013","unstructured":"Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3:225\u201338.","journal-title":"Am J Blood Res"},{"key":"102_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.12545","volume":"163","author":"LM Ball","year":"2013","unstructured":"Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013;163:501\u20139.","journal-title":"Br J Haematol"},{"key":"102_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.bbmt.2011.07.023","volume":"18","author":"BL von","year":"2012","unstructured":"von BL, Sundberg B, Lonnies L, Sander B, Karbach H, Hagglund H, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant. 2012;18:557\u201364.","journal-title":"Biol Blood Marrow Transplant"},{"key":"102_CR13","doi-asserted-by":"publisher","first-page":"e0136991","DOI":"10.1371\/journal.pone.0136991","volume":"10","author":"X Chen","year":"2015","unstructured":"Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y. Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0136991.","journal-title":"PLoS ONE"},{"key":"102_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3324\/haematol.2015.140368","volume":"101","author":"Z Kuci","year":"2016","unstructured":"Kuci Z, Bonig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, et al. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica. 2016;101:985\u201394.","journal-title":"Haematologica"},{"key":"102_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"102_CR16","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"102_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1423-0410.2012.01619.x","volume":"104","author":"H Eichler","year":"2013","unstructured":"Eichler H, Schrezenmeier H, Schallmoser K, Strunk D, Nystedt J, Kaartinen T, et al. Donor selection and release criteria of cellular therapy products. Vox Sang. 2013;104:67\u201391.","journal-title":"Vox Sang"},{"key":"102_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2307\/2530374","volume":"34","author":"RL Prentice","year":"1978","unstructured":"Prentice RL, Kalbfleisch JD, Peterson AV Jr., Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541\u201354.","journal-title":"Biometrics"},{"key":"102_CR19","doi-asserted-by":"crossref","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics. 1988;16:1141\u201354.","DOI":"10.1214\/aos\/1176350951"},{"key":"102_CR20","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.bbmt.2010.05.019","volume":"16","author":"JE Levine","year":"2010","unstructured":"Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolanos-Meade J, et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant. 2010;16:1693\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"102_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/bmt.2011.41","volume":"47","author":"RM Saliba","year":"2012","unstructured":"Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 2012;47:125\u201331.","journal-title":"Bone Marrow Transplant"},{"key":"102_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3324\/haematol.2013.093062","volume":"99","author":"Y Inamoto","year":"2014","unstructured":"Inamoto Y, Martin PJ, Storer BE, Mielcarek M, Storb RF, Carpenter PA. Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. Haematologica. 2014;99:385\u201391.","journal-title":"Haematologica"},{"key":"102_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/sj.bmt.1705100","volume":"36","author":"P Windrum","year":"2005","unstructured":"Windrum P, Morris TC, Drake MB, Niederwieser D, Ruutu T. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant. 2005;36:601\u20133.","journal-title":"Bone Marrow Transplant"},{"key":"102_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","volume":"20","author":"J Kurtzberg","year":"2014","unstructured":"Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014;20:229\u201335.","journal-title":"Biol Blood Marrow Transplant"},{"key":"102_CR25","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/j.bbmt.2009.12.057","volume":"16","author":"PJ Martin","year":"2010","unstructured":"Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant. 2010;16:S169\u2013S70.","journal-title":"Biol Blood Marrow Transplant"},{"key":"102_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","volume":"20","author":"M Introna","year":"2014","unstructured":"Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014;20:375\u201381.","journal-title":"Biol Blood Marrow Transplant"},{"key":"102_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbmt.2010.04.014","volume":"17","author":"VK Prasad","year":"2011","unstructured":"Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011;17:534\u201341.","journal-title":"Biol Blood Marrow Transplant"},{"key":"102_CR28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/bmt.2016.317","volume":"52","author":"U Salmenniemi","year":"2017","unstructured":"Salmenniemi U, Itala-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transplant. 2017;52:606\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"102_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2017.35","volume":"52","author":"GM Dotoli","year":"2017","unstructured":"Dotoli GM, De Santis GC, Orellana MD, de Lima PK, Caruso SR, Fernandes TR, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:859\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"102_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/stem.2224","volume":"34","author":"F Dalowski von","year":"2016","unstructured":"von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N, et al. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome. Stem Cells. 2016;34:357\u201366.","journal-title":"Stem Cells"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0102-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:11:26Z","timestamp":1684617086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0102-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0102-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,29]]},"assertion":[{"value":"19 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PB, ZK, HB, and SK are holding IP on the MSC production. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}